Ferroptosis triggers PGE2 production to help cancer cells escape immune attack
Researchers found that dying cancer cells via ferroptosis release prostaglandin E2 to suppress the immune system in mouse models.
Lipid peroxidation activates immune suppression
Ferroptotic cancer cells undergo membrane permeabilization that allows calcium ions to enter the cell interior. This influx of calcium activates p38 MAPK signalling pathways within the dying tumour tissue. The activated pathway drives aberrant production of prostaglandin E2 which limits anticancer T cell responses. Type 1 conventional dendritic cells fail to stimulate CD8+ T cells effectively in this environment.
Mechanism blocks effective tumour elimination
Studies used mouse models with BRAF mutations and NRAS mutations alongside breast and colon cancer lines. These specific genetic alterations created the conditions for ferroptosis to occur without immediate cell death success. The resulting PGE2 production uncouples from the actual process of killing the malignant cells. This molecular program prevents the immune system from eradicating difficult-to-treat cancers resistant to current therapies.
Targeting PGE2 restores immunity
Ablating prostaglandin E2 production or disrupting its signalling restored cDC1-mediated anticancer CD8+ T cell responses. Effective tumour elimination followed when researchers interfered with this specific immune-inhibitory pathway selectively. The findings identify a key mechanism that limits antitumour immunity during ferroptosis induction. This mechanism could be exploited for future cancer therapy strategies against resistant tumours.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.